These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 11490227)

  • 1. Clinical role of F-18 fluorodeoxyglucose positron emission tomography for detection and management of renal cell carcinoma.
    Ramdave S; Thomas GW; Berlangieri SU; Bolton DM; Davis I; Danguy HT; Macgregor D; Scott AM
    J Urol; 2001 Sep; 166(3):825-30. PubMed ID: 11490227
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prospective diagnostic accuracy study of F-18 fluorodeoxyglucose-positron emission tomography/computed tomography in the evaluation of indeterminate renal masses.
    Ozülker T; Ozülker F; Ozbek E; Ozpaçaci T
    Nucl Med Commun; 2011 Apr; 32(4):265-72. PubMed ID: 21301376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. F-18 fluorodeoxyglucose positron emission tomography in the evaluation of distant metastases from renal cell carcinoma.
    Majhail NS; Urbain JL; Albani JM; Kanvinde MH; Rice TW; Novick AC; Mekhail TM; Olencki TE; Elson P; Bukowski RM
    J Clin Oncol; 2003 Nov; 21(21):3995-4000. PubMed ID: 14581422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of 18F-fluorodeoxyglucose positron-emission tomography/computed tomography for the postoperative surveillance of advanced renal cell carcinoma.
    Park JW; Jo MK; Lee HM
    BJU Int; 2009 Mar; 103(5):615-9. PubMed ID: 19007371
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of FDG uptake by renal malignancies (primary tumor or metastases) using a coincidence detection gamma camera.
    Montravers F; Grahek D; Kerrou K; Younsi N; Doublet JD; Gattegno B; Rossert J; Costa de Beauregard MA; Thibault P; Talbot JN
    J Nucl Med; 2000 Jan; 41(1):78-84. PubMed ID: 10647608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic role of [F-18]-FDG positron emission tomography in restaging renal cell carcinoma.
    Jadvar H; Kherbache HM; Pinski JK; Conti PS
    Clin Nephrol; 2003 Dec; 60(6):395-400. PubMed ID: 14690256
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Positron emission tomography for prostate, bladder, and renal cancer.
    Schöder H; Larson SM
    Semin Nucl Med; 2004 Oct; 34(4):274-92. PubMed ID: 15493005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use of fluorodeoxyglucose F 18 positron emission tomography for detection of renal cell carcinoma.
    Kang DE; White RL; Zuger JH; Sasser HC; Teigland CM
    J Urol; 2004 May; 171(5):1806-9. PubMed ID: 15076281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 18F-FDG-PET/CT in potentially advanced renal cell carcinoma: a role in treatment decisions and prognosis estimation.
    Ferda J; Ferdova E; Hora M; Hes O; Finek J; Topolcan O; Kreuzberg B
    Anticancer Res; 2013 Jun; 33(6):2665-72. PubMed ID: 23749925
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sarcomatoid renal cell carcinoma: rapid dissemination detected on FDG PET-CT.
    Thambugala GM; Mohamed A; O' Neill GF; Fulham MJ
    Australas Radiol; 2006 Dec; 50(6):604-6. PubMed ID: 17107535
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of (18) F-fluorodeoxyglucose (FDG)-positron-emission tomography/computed tomography (PET/CT) on management of patients with carcinoma invading bladder muscle.
    Mertens LS; Fioole-Bruining A; Vegt E; Vogel WV; van Rhijn BW; Horenblas S
    BJU Int; 2013 Oct; 112(6):729-34. PubMed ID: 23790129
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restaging clear cell renal carcinoma with 18F-FDG PET/CT.
    Fuccio C; Ceci F; Castellucci P; Spinapolice EG; Palumbo R; D'Ambrosio D; Bernardo A; Brunocilla E; Schiavina R; Maffione AM; Chondrogiannis S; Grassetto G; Colletti PM; Rubello D; Fanti S; Trifirò G
    Clin Nucl Med; 2014 Jun; 39(6):e320-4. PubMed ID: 24566409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic value of F-18 FDG PET/CT for local and distant disease relapse surveillance in surgically treated RCC patients: Can it aid in establishing consensus follow up strategy?
    Elahmadawy MA; Elazab MSS; Ahmed S; Salama M
    Nucl Med Rev Cent East Eur; 2018; 21(2):85-91. PubMed ID: 30070347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET scans for decision-making in metastatic renal cell carcinoma: a single-institution evaluation.
    Dilhuydy MS; Durieux A; Pariente A; de Clermont H; Pasticier G; Monteil J; Ravaud A
    Oncology; 2006; 70(5):339-44. PubMed ID: 17164590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical utility of
    Nakamoto Y; Ishimori T; Shimizu Y; Sano K; Togashi K
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1524-1530. PubMed ID: 30847538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of FDG PET-CT in recurrent renal cell carcinoma.
    Kumar R; Shandal V; Shamim SA; Jeph S; Singh H; Malhotra A
    Nucl Med Commun; 2010 Oct; 31(10):844-50. PubMed ID: 20661166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. F-18 FDG PET in detecting renal cell carcinoma.
    Ak I; Can C
    Acta Radiol; 2005 Dec; 46(8):895-9. PubMed ID: 16392617
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent renal cell carcinoma: clinical and prognostic value of FDG PET/CT.
    Alongi P; Picchio M; Zattoni F; Spallino M; Gianolli L; Saladini G; Evangelista L
    Eur J Nucl Med Mol Imaging; 2016 Mar; 43(3):464-73. PubMed ID: 26268680
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The potential clinical value of FDG-PET for recurrent renal cell carcinoma.
    Nakatani K; Nakamoto Y; Saga T; Higashi T; Togashi K
    Eur J Radiol; 2011 Jul; 79(1):29-35. PubMed ID: 20015602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.